Your browser is no longer supported. Please, upgrade your browser.
AKRX Akorn, Inc. daily Stock Chart
Akorn, Inc.
Index- P/E22.82 EPS (ttm)1.46 Insider Own1.60% Shs Outstand124.41M Perf Week0.00%
Market Cap4.16B Forward P/E18.72 EPS next Y1.79 Insider Trans0.00% Shs Float99.33M Perf Month0.60%
Income183.40M PEG4.56 EPS next Q0.40 Inst Own84.20% Short Float6.93% Perf Quarter34.88%
Sales1.10B P/S3.77 EPS this Y20.30% Inst Trans4.48% Short Ratio1.64 Perf Half Y53.89%
Book/sh7.00 P/B4.77 EPS next Y9.78% ROA9.30% Target Price30.25 Perf Year26.70%
Cash/sh2.48 P/C13.46 EPS next 5Y5.00% ROE22.40% 52W Range17.61 - 35.40 Perf YTD53.05%
Dividend- P/FCF21.24 EPS past 5Y28.90% ROI14.80% 52W High-5.62% Beta1.35
Dividend %- Quick Ratio3.20 Sales past 5Y52.20% Gross Margin59.90% 52W Low89.72% ATR0.16
Employees2261 Current Ratio4.20 Sales Q/Q-5.60% Oper. Margin28.60% RSI (14)50.37 Volatility0.39% 0.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-2.70% Profit Margin16.60% Rel Volume0.26 Prev Close33.58
ShortableYes LT Debt/Eq0.93 EarningsJul 03 BMO Payout0.00% Avg Volume4.20M Price33.41
Recom3.00 SMA200.10% SMA500.57% SMA20029.43% Volume1,109,263 Change-0.51%
Apr-25-17Downgrade Piper Jaffray Overweight → Neutral
Apr-25-17Downgrade Jefferies Buy → Hold
Apr-25-17Downgrade Gabelli & Co Buy → Hold
Mar-10-17Reiterated WallachBeth Hold $22 → $25
Dec-01-16Initiated Goldman Sell
Nov-07-16Downgrade WallachBeth Buy → Hold $40 → $22
Nov-07-16Downgrade BofA/Merrill Buy → Underperform
Nov-04-16Downgrade RBC Capital Mkts Outperform → Sector Perform $37 → $24
Sep-15-16Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated WallachBeth Buy $39 → $40
Aug-05-16Downgrade Deutsche Bank Buy → Hold $33 → $33
Aug-02-16Downgrade Raymond James Outperform → Mkt Perform
Mar-18-16Reiterated Deutsche Bank Buy $40 → $33
Feb-12-16Reiterated RBC Capital Mkts Outperform $52 → $37
Dec-02-15Upgrade Nomura Neutral → Buy
Sep-29-15Initiated Nomura Neutral
Sep-09-15Initiated JMP Securities Mkt Perform
Jul-21-15Initiated Susquehanna Neutral
Jun-03-15Initiated Raymond James Outperform $53
Apr-27-15Downgrade Piper Jaffray Overweight → Neutral $66 → $53
Jun-22-17 08:00PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Akorn, Inc. GlobeNewswire
Jun-19-17 02:52PM  ETFs with exposure to Akorn, Inc. : June 19, 2017 Capital Cube
09:27AM  Top 3 Companies Owned by Valeant (VRX) Investopedia
Jun-16-17 11:45AM  Akorn, Inc. :AKRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
May-23-17 03:05PM  Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX PR Newswire
May-03-17 03:45AM  Fresenius Tops Estimates, Raises Outlook Bloomberg Video
May-01-17 07:05PM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Akorn, Inc. -AKRX Accesswire
01:07PM  How Trumps First 100 Days Affected the Healthcare Industry Motley Fool
09:29AM  Fresenius Buys Akorn -- What Now? Motley Fool
Apr-30-17 04:20PM  Merger Buzz Drives Akorn to Top of Health Chart in April
06:00AM  INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and Encourages Shareholders to Contact the Firm for Additional Information Business Wire
Apr-28-17 07:17PM  Lifshitz & Miller LLP Announces Investigation of AdvancePierre Foods Holdings, Inc., Akorn, Inc., AllianceMMA, Inc., Altisource Portfolio Solutions, DelTaco Restaurants, Inc., Express Scripts Holding Company, China Unicom (Hong Kong) Limited, and Global Eagle Entertainment Inc. PR Newswire
Apr-26-17 05:28PM  SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and Encourages Investors to Contact the Firm for Additional Information Business Wire
03:10PM  Akorn, Inc. -- Moody's reviews Akorn's ratings for upgrade Moody's
11:30AM  Fresenius US Finance II, Inc. -- Moody's affirms Fresenius SE's Baa3 issuer rating, outlook stable Moody's
Apr-25-17 07:46PM  Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up
06:40PM  AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akorn, Inc. PR Newswire
02:46PM  [$$] Fresenius Makes Two Acquisitions to Boost Kabi Clinical Unit The Wall Street Journal
12:02PM  Harwood Feffer LLP Announces Investigation of Akorn, Inc. PR Newswire
11:38AM  AKORN, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to Fresenius Kabi Business Wire
10:38AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Akorn, Inc. to Fresenius Kabi for $34 Per Share is Fair to Shareholders - AKRX Accesswire
09:03AM  Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More
09:00AM  Fresenius Spends Billions On a Falling Akorn Bloomberg
08:03AM  AKORN (AKRX) ALERT: J&W Launches Investigation into the Sale of Akorn; Is $34 a Fair Price? PR Newswire
06:01AM  Fresenius and Merck Stocks Top DAX on Biosimilars Deal
04:17AM  Fresenius picks up M&A pace with Akorn, Merck KGaA deals Reuters
Apr-24-17 06:33PM  Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals Reuters
06:30PM  Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals Reuters
05:13PM  Germany's Fresenius Kabi to buy Akorn for $4.3 billion MarketWatch
05:01PM  Fresenius Buys Akorn for $4.3 Billion in U.S. Expansion Bloomberg
04:58PM  Fresenius Kabi to Acquire Akorn Business Wire
12:45PM  Exclusive: Fresenius nears deal to acquire Akorn - sources Reuters
Apr-21-17 08:40AM  4 Stocks With Strong Technical Momentum Benzinga
Apr-11-17 02:47PM  Analyst: Akorn Could Be Sold For As Much As $34 Per Share, But There's Double-Digits Downside If Deal Doesn't Happen Benzinga
Apr-10-17 04:31PM  Akorn Acquisition Talks Send Generic Drugmakers Into Orbit Investor's Business Daily +9.17%
02:07PM  Here's Why Akorn Inc. Rose as Much as 12.8% Today Motley Fool
01:00PM  Akorn Takeover Talk Unsurprising Morningstar
12:25PM  Akorn Acquisition Talks Send Generic Drugmakers Into Orbit Investor's Business Daily
12:18PM  Akorn, Inc.: Leads amongst peers with strong fundamentals Capital Cube
11:26AM  Story Stocks from
09:40AM  Stocks Open Higher; Analyst Note Lifts Tesla; Canada Goose Rises Investor's Business Daily
09:15AM  The Market In 5 Minutes Benzinga
Apr-08-17 07:26AM  [$$] Fresenius in Talks to Buy U.S. Drug Maker Akorn The Wall Street Journal
Apr-07-17 06:12PM  Germany's Fresenius in talks to buy generic drugmaker Akorn Reuters +18.04%
05:58PM  Akorn Confirms Discussions with Fresenius Kabi GlobeNewswire
04:39PM  Akorn Launches To Six-Month High On Fresenius Takeover Rumor Investor's Business Daily
04:34PM  Why Diana Shipping, Akorn, and Granite Construction Jumped Today Motley Fool
03:44PM  ETFs with exposure to Akorn, Inc. : April 7, 2017 Capital Cube
03:05PM  Jury awards $20M in Georgia couple case's against drug maker Associated Press
02:52PM  Akorn shares surge 20% on report Germany's Fresenius is mulling a bid MarketWatch
02:45PM  Germany's Fresenius weighing bid for generic drugmaker Akorn -Bbg Reuters
01:41PM  Why Valeant Just Popped
01:04PM  Fresenius Says It's in Talks to Buy Generic Drugmaker Akorn Bloomberg
Mar-20-17 02:55PM  Is The Market Expensive? Buffett Says No Forbes
02:55PM  Is The Market Expensive? Buffett Says No at Forbes
Mar-13-17 08:15AM  Blog Coverage Mylan Announces Launch of Generic Version of Pfizer's Antidepressant PRISTIQ in US Accesswire
Mar-07-17 01:04PM  AKORN INC Financials
Mar-06-17 01:27PM  ETFs with exposure to Akorn, Inc. : March 6, 2017 Capital Cube -7.15%
01:27PM  ETFs with exposure to Akorn, Inc. : March 6, 2017
01:25PM  Does Reward Potential Still Outweigh The Risk In Akorn Shares? Benzinga
12:00PM  Bullish and Bearish Reversals in the Market
12:00PM  Bullish and Bearish Reversals in the Market
10:20AM  Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy 24/7 Wall St.
10:10AM  New Strong Sell Stocks for March 6th Zacks
08:07AM  Analysts' Actions -- FedEx, GoPro, Garmin, HP and More
Mar-03-17 10:25AM  Perrigo Joins Firms With Generic Drugs Under U.S. Glare Bloomberg
10:25AM  Perrigo Joins Firms With Generic Drugs Under U.S. Glare
Mar-02-17 10:05AM  Akorn, Inc. :AKRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 +5.17%
08:37AM  AKORN INC Files SEC form 8-K, Regulation FD Disclosure
08:25AM  Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP GlobeNewswire
07:00AM  7 Stocks Trending With Monster Volume
Mar-01-17 10:00AM  Akorn Inc Earnings Call scheduled for 10:00 am ET today
07:43AM  Akorn meets 4Q profit forecasts
07:31AM  AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition
07:07AM  Q4 2016 Akorn Inc Earnings Release - Before Market Open
07:00AM  Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance GlobeNewswire
Feb-28-17 05:30PM  Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP GlobeNewswire -5.75%
Feb-13-17 07:46AM  Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : February 13, 2017
Feb-06-17 07:30AM  Akorn to Report Fourth Quarter and Full Year 2016 Results GlobeNewswire
Jan-23-17 02:46PM  8 Stocks Trading Below Peter Lynch Value
Jan-19-17 01:27PM  Value Investing 2017: 3 Stocks to Put on Your Radar at Motley Fool
Jan-18-17 07:00PM  Casualty List Has Done Well; Here's the Latest
08:04AM  Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : January 18, 2017
Jan-03-17 10:17AM  Akorn, Inc. Value Analysis (NASDAQ:AKRX) : January 3, 2017
Jan-02-17 07:07AM  Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : January 2, 2017
Jan-01-17 09:26PM  Integer Investments: Akorn Has 100% Upside Potential
Dec-21-16 07:30AM  Akorn to Present at 35th Annual J.P Morgan Healthcare Conference GlobeNewswire
Dec-19-16 05:06PM  AKORN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-15-16 07:54AM  [$$] Akorn Is a Best Idea for 2017 at
Dec-12-16 05:52PM  Why Baytex Energy, Akorn, and Alamos Gold Jumped Today at Motley Fool +8.66%
03:04PM  Why Akorn, Inc. Shares Are Surging 10% at Motley Fool
07:55AM  AKORN INC Files SEC form 8-K, Other Events
07:00AM  Akorn Announces Completion of FDA Re-inspection of Decatur Facility GlobeNewswire
Dec-09-16 12:22PM  Wall Street analysts expect these mid-cap stocks to rise up to 53% in 2017 at MarketWatch
Dec-08-16 12:56PM  Why Shares of Drug Maker Akorn Are a Buy After Losing 50% in 2016
12:10PM  ETFs with exposure to Akorn, Inc. : December 8, 2016
10:35AM  3 Reasons Akorn Inc. Could Fall at Motley Fool
Dec-07-16 04:12PM  Drug Stocks Topple On Donald Trump's Pledge To Bring Down Drug Prices
Dec-02-16 09:49AM  3 Reasons Akorn Inc. Stock Could Rise at Motley Fool
Dec-01-16 07:13AM  Coverage initiated on Akorn by Goldman -5.80%
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. This segment's primary products include Atropine Sulfate Ophthalmic Solution; Clobetasol Propionate Cream And Ointment; Ephedrine Sulfate Injection; Lidocaine Ointment; Methylene Blue Injection; Myorisan soft gelatin capsules; Nembutal sodium solution; Phenylephrine Hydrochloride Ophthalmic Solution; and Zioptan tafluprost ophthalmic solution. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Graves Adrienne LDirectorFeb 08Option Exercise12.8720,000257,40024,661Feb 10 04:30 PM
ABRAMOWITZ KENNETHDirectorAug 15Sale30.631,16635,71619,620Aug 16 04:32 PM
ABRAMOWITZ KENNETHDirectorAug 12Sale30.291,52546,19520,786Aug 16 04:32 PM